Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunovaccine has signed a collaborative research agreement with OncoTherapy Science to explore the efficacy of their novel peptide cancer antigen in Immunovaccine's DepoVax vaccine delivery and enhancement platform.
Subscribe to our email newsletter
Immunovaccine claims that its DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology.
Immunovaccine is currently testing the safety and tolerability of DepoVax in a Phase I clinical trial with DPX-0907, a peptide-based therapeutic cancer vaccine targeting patients with breast, ovarian and prostate cancer.
Immunovaccine R&D vice president Marc Mansour said that they are pleased to be collaborating with OncoTherapy Science and evaluating how the DepoVax technology may enhance the potential of these select peptide antigens to create a highly potent, highly specific vaccine candidate.